CA3163342A1 - Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease - Google Patents

Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Info

Publication number
CA3163342A1
CA3163342A1 CA3163342A CA3163342A CA3163342A1 CA 3163342 A1 CA3163342 A1 CA 3163342A1 CA 3163342 A CA3163342 A CA 3163342A CA 3163342 A CA3163342 A CA 3163342A CA 3163342 A1 CA3163342 A1 CA 3163342A1
Authority
CA
Canada
Prior art keywords
subject
unit dosage
dosage form
active agent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3163342A
Other languages
English (en)
French (fr)
Inventor
John Patrick Casey Jr.
David Arthur Berry
Timothy F. Briggs
Leonard Buckbinder
Mi-Jeong Kim
Anna LIANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations V Inc
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of CA3163342A1 publication Critical patent/CA3163342A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3163342A 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease Pending CA3163342A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944282P 2019-12-05 2019-12-05
US62/944,282 2019-12-05
US202063074785P 2020-09-04 2020-09-04
US63/074,785 2020-09-04
PCT/US2020/063281 WO2021113620A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
CA3163342A1 true CA3163342A1 (en) 2021-06-10

Family

ID=76221219

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3163342A Pending CA3163342A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Country Status (8)

Country Link
US (1) US20220296563A1 (https=)
EP (1) EP4069209A4 (https=)
JP (1) JP2023504547A (https=)
CN (1) CN114901267A (https=)
AU (1) AU2020396554A1 (https=)
BR (1) BR112022010672A2 (https=)
CA (1) CA3163342A1 (https=)
WO (1) WO2021113620A1 (https=)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2258173A1 (en) * 1974-01-22 1975-08-18 Expl Marques Brevets Et Acetylsalicylic acid 2-p-chlorophenoxy isobutyric acid compsns - with anticoagulant and hypocholesterolaemic effects
US4276430A (en) * 1976-12-15 1981-06-30 The Procter & Gamble Company Analgesic and anti-inflammatory compounds and compositions containing same
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
FR2720936B1 (fr) * 1994-06-08 1997-04-30 Synthelabo Poudres à base de métoclopramide et de paracétamol ou de dérivés d'acide acétylsalicylique.
WO1996016639A1 (en) * 1994-12-01 1996-06-06 Cibus Pharmaceutical, Inc. Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
DE19726871C1 (de) * 1997-06-24 1999-03-04 Werner Kreutz Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
US20090036516A1 (en) * 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
PT2056815E (pt) * 2006-08-16 2013-04-03 Amderma Pharmaceuticals Llc Utilização de derivados de 2,5-dihidroxibenzeno para tratar dermatite
EP2445344A4 (en) * 2009-06-25 2013-01-23 Pozen Inc METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY
US8834858B2 (en) * 2010-07-02 2014-09-16 Solvotrin Therapeutics Ltd. Treatment for dyslipidemia
US8287904B2 (en) * 2010-08-19 2012-10-16 Lionel Borkan Stable soft capsule dosage form for acetylsalicylic acid
US11771659B2 (en) * 2017-06-19 2023-10-03 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway
CA3102404A1 (en) * 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
EP3801489A4 (en) * 2018-06-05 2022-03-30 Flagship Pioneering Innovations V, Inc. ACYLATED DRUGS AND METHODS OF USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP7645244B2 (ja) * 2019-08-30 2025-03-13 中国科学院動物研究所 代謝性疾患と闘うために使用される組成物およびその組成物の使用

Also Published As

Publication number Publication date
BR112022010672A2 (pt) 2022-08-16
CN114901267A (zh) 2022-08-12
US20220296563A1 (en) 2022-09-22
AU2020396554A1 (en) 2022-07-07
EP4069209A4 (en) 2024-04-10
WO2021113620A8 (en) 2021-07-22
EP4069209A1 (en) 2022-10-12
WO2021113620A1 (en) 2021-06-10
JP2023504547A (ja) 2023-02-03

Similar Documents

Publication Publication Date Title
JP7592140B2 (ja) 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法
AU2016235263A1 (en) Methods of treating liver disease using indane acetic acid derivatives
WO2010040286A1 (zh) 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
CA2717692A1 (en) N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation
WO2020077361A1 (en) Compounds and methods of their use
EP3059232B1 (en) Chromene derivatives substituted by alkoxide as inhibitors of the tcr-nck interaction
JP2007534771A (ja) 炎症性疾患の治療におけるフェノキシアルキルカルボン酸誘導体
US20220296563A1 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
US20220296555A1 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN119350175B (zh) 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途
US11958869B2 (en) Ruthenium arene Schiff-base complexes and uses thereof
HUE028052T2 (en) Spinozinase-inhibiting prodrugs
WO2006132196A1 (ja) β３作動薬を含有する新規な医薬
CA2532805A1 (en) Pharmaceutical composition
CN118772098B (zh) 一类具有抗炎保肝活性呋喃类化合物、其制备及用途
EA015503B1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм
KR20050044853A (ko) 카르복실산 유도체 화합물 및 이 화합물을 유효성분으로서함유하는 약제
CA2717495A1 (en) Fullerene therapies for inflammation
KR100881040B1 (ko) 의약 조성물
CN119745887A (zh) 小分子激动剂tepp-46在制备预防和/或治疗主动脉瘤及相关心血管疾病的药物中的应用
HK40055053A (en) Pharmaceutical composition comprising hydroquinone derivative for preventing or treating obesity or non-alcoholic steatohepatitis
JP2019089720A (ja) 化合物又はその薬学的に許容され得る塩、筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤
WO2012056229A1 (en) Inflammatory disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260115